ACADIA PHARMACEUTICALS INC. Operating Lease Right-of-Use Assets
ACADIA PHARMACEUTICALS INC. (ACAD) had Operating Lease Right-of-Use Assets of $69.42 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $69.42M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $46.27M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $47.35M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $49.67M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $69.42M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $46.27M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $47.35M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $49.67M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.99M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $50.61M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $46.57M 10-K · filed 2026-02-26 |
| 2024-09-30 | $44.25M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $52.39M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $54.28M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $51.85M 10-K · filed 2025-02-27 |
| 2023-09-30 | $50.76M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $52.38M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $54.15M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $55.57M 10-K · filed 2024-02-28 |
| 2022-09-30 | $56.62M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $57.42M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $58.19M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $58.27M 10-K · filed 2023-02-28 |
| 2021-09-30 | $60.03M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $61.37M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $63.11M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $47.28M 10-K · filed 2022-03-01 |
| 2020-09-30 | $48.23M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $7.88M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $8.61M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $9.52M 10-K · filed 2021-02-25 |
| 2019-09-30 | $9.96M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $10.82M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $10.92M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |